Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain - Wikidata - wikimedia - TriplyDB

Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain

Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain

http://www.wikidata.org/entity/Q35946627

about

Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization Principles of antibody-mediated TNF receptor activation Immunotherapy in the treatment of non-small cell lung cancer Science gone translational: the OX40 agonist story Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging.Control of immunity by the TNFR-related molecule OX40 (CD134)OX40 is a potent immune-stimulating target in late-stage cancer patients.Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer.Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus.The role of TNF superfamily members in T-cell function and diseases.Integrating costimulatory agonists to optimize immune-based cancer therapies.Costimulatory and coinhibitory receptors in anti-tumor immunity Signaling through OX40 enhances antitumor immunity.T cell co-stimulatory molecules: a co-conspirator in the pathogenesis of eosinophilic esophagitis?Novel antibodies targeting immune regulatory checkpoints for cancer therapy.Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy OX40, OX40L and Autoimmunity: a Comprehensive Review.Delivering safer immunotherapies for cancer.Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.Immunosilencing a highly immunogenic protein trimerization domain.Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer.Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.

P2860

Q24318411-5E986D1E-8C99-482A-91CE-D755F306A2BB Q26796270-F7D2CE2B-3A61-4627-A734-0354717BE3C1 Q27000382-AF5BA28A-22F9-4022-9F19-84AC8627E314 Q27022436-ABE825D1-A005-4B37-BACE-CDB1F70ACF5B Q33402880-C88D5628-ACDA-4289-9DE7-A73FFA99F976 Q33624312-C9BC3F4D-A1FE-4A33-AEC4-70E89963237F Q33899607-896906EA-A13B-4EFC-A304-EA4D0EA0D1DC Q34381674-9CBFBDEA-D8C7-4511-B2A9-0E0E91A3449C Q36851678-0810F220-11E0-4E76-A974-95E63C13F839 Q37177498-E547B86D-96F2-4C38-96B6-7AAB1339A9AD Q37332068-8CA8353F-7E12-4E9A-9BD7-0A25B4EA1673 Q37352989-04931C59-2DE3-4CAB-AC15-6E514E92921F Q37474920-5DC903E4-8B8E-417F-BB2B-A7EF761E9947 Q37809163-A01792DF-726A-41DA-98E5-0480A14552EC Q38086114-E052FE41-7AE6-4886-9D0B-E4D142EF2F17 Q38108836-9A018EE7-7423-415F-B0F4-1747D1B400C4 Q38120535-1ED33266-C76F-44D0-A22C-046461EE625A Q38214095-6FFD4BD3-4CA1-4D62-81E7-FFB2550D4F9B Q38555213-8A92C079-C325-4ECE-9D2C-FCAD8A3E324C Q39330984-BB722B05-C075-47A6-BF61-22487607F3B9 Q40560816-D3691BB4-CFDB-4653-AEF3-AC9784E0F9C2 Q41506957-D90A5639-4AD1-41EA-88EE-FBCA8A70FFA9 Q47155705-40D9BE5B-9C7F-4EBE-8511-CB367B512A2B Q53078816-C47A1AFF-BF19-414E-AD9E-19205AAEFA54

P2860

Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain

http://www.wikidata.org/entity/Q35946627

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Development and characterizati ...... iled-coil trimerization domain

@ast

Development and characterizati ...... iled-coil trimerization domain

@en

type

label

Development and characterizati ...... iled-coil trimerization domain

@ast

Development and characterizati ...... iled-coil trimerization domain

@en

prefLabel

Development and characterizati ...... iled-coil trimerization domain

@ast

Development and characterizati ...... iled-coil trimerization domain

@en

P1433

Q35946627-85A9FFAB-4768-4DDB-9D6C-24CC9BB03B09

P1476

Q35946627-71293569-8741-491B-A95E-A856B73648B9

P2093

Q35946627-092EA793-FBD5-4BD0-A8A9-29C441AA1533

Q35946627-10945CFD-4241-4F0A-9915-00FF5CC9ACF7

Q35946627-1C5E7E84-ADD0-45DA-B1F6-CEEBAA6180DB

Q35946627-6EBE85EA-8756-4D34-9CCC-A1C95297CCBB

Q35946627-86289C9C-5F15-479E-9999-D6DC91E77E75

Q35946627-D9AC2814-1066-44CB-86FD-05A9F4231D58

Q35946627-F192CE01-B489-46FA-8040-3547E2885F8F

P2860

Q35946627-05828FB7-135D-404B-9CEA-F91DBDD29CA1

Q35946627-123BD6B2-4711-4A98-8A88-D30BA72A335F

Q35946627-13B388B8-B85E-4258-8A6D-DF903284B6CC

Q35946627-1AE794E7-F6FA-41D4-B81F-332190E4A505

Q35946627-25FB1BA4-01BC-4D79-8E1C-33815947CFBE

Q35946627-4E6F65C2-B0E5-416D-9A58-0BC7BA0B300A

Q35946627-5B9B162F-7A47-4B62-854D-DEA4FA4709CF

Q35946627-5D3EB1CE-3624-4CC5-A9A1-439FB320550F

Q35946627-67E873A7-B4A6-48B2-9E5C-E6E44856FF2D

Q35946627-700E61B1-2A78-4837-8135-995BE5C08D89

P304

Q35946627-5E7B064E-3AC7-4E3A-8B3C-50F5923B6CBE

P31

Q35946627-C3857841-9F25-4BD4-9A2B-25A5C9C15E48

P356

Q35946627-76EABAE5-FF11-48FC-9055-C94FA2ECC232

P433

Q35946627-93CBB3AB-CEE5-4B03-8EF0-14599689A544

P478

Q35946627-A76F769A-235A-422B-9EF9-61BFC3629563

P577

Q35946627-CF3A5931-A6EB-4DE3-8CF1-DEE3D30700D7

P5875

Q35946627-1441AEBA-9140-47BF-B9A4-D482FAD64AE7

P698

Q35946627-F8521770-1EA6-4D1C-91F0-955CF51651E8

P932

Q35946627-7587007A-FEFE-4358-8324-4C194D452901

P356

J.MOLIMM.2007.02.004

P1433

Molecular Immunology

P1476

Development and characterizati ...... iled-coil trimerization domain

@en

P2093

Andrew D Weinberg

http://www.w3.org/2001/XMLSchema#string

Brendan D Curti

http://www.w3.org/2001/XMLSchema#string

Carmen Peters

http://www.w3.org/2001/XMLSchema#string

Hong-Ming Hu

http://www.w3.org/2001/XMLSchema#string

Nicholas P Morris

http://www.w3.org/2001/XMLSchema#string

Ryan Montler

http://www.w3.org/2001/XMLSchema#string

Walter J Urba

http://www.w3.org/2001/XMLSchema#string

P2860

A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants

Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?

TNF/TNFR family members in costimulation of T cell responses

Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts

Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes--a molecule related to nerve growth factor receptor

The tissue form of type VII collagen is an antiparallel dimer

On the analysis of protein self-association by sedimentation velocity analytical ultracentrifugation

A method for directly fitting the time derivative of sedimentation velocity data and an alternative algorithm for calculating sedimentation coefficient distribution functions.

A single EGF-like motif of laminin is responsible for high affinity nidogen binding.

The molecular architecture of the TNF superfamily.

P304

3112-3121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.MOLIMM.2007.02.004

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6433785

http://www.w3.org/2001/XMLSchema#string

P698

17374396

http://www.w3.org/2001/XMLSchema#string

P932

1950941

http://www.w3.org/2001/XMLSchema#string